Republican healthcare policies

I have attended more scientific and medical conferences than I care to remember. One thing that never failed to impress me was the large number of foreign-born young scientists attracted to our country and our great universities. I wrote an article titled, Who is Afraid of Immigration, noting how many of those scientists arrived as students from countries that smothered independent thoughts and initiatives, and chose to stay in the country where freedom reigned and the possibilities were unlimited. But then 9/11 happened, and our country was seized with a dark mood of suspicion and outright xenophobia. Young students and scientists could not join our scientific enterprise, to our great detriment. What we lost was the great intellectual cross-fertilization that animated our progress. The rise of xenophobic obsessions, coupled with hostility toward Science by the Bush administration wrought incalculable long-term harm to American science. Yes, we are still garnering a lot of Nobel Prizes, but don’t let it deceive you—those brilliant scientists are awarded their respective prizes for work done over decades, during the golden age of American science.


Mirror, mirror on the wall…

How do we measure the impact a scientist is making in his field of research? Not by the number of papers. Most scientific breakthroughs are made by a handful of researchers, and their findings published in a few seminal papers. The rest are “backing and filling”, closing gaps in our knowledge, confirming, making marginal progress. Don’t get me wrong, this is an important and indispensable aspect of the scientific endeavor; it prepares the ground for the next breakthrough. But the impact individual papers of this “second rung” research is naturally smaller.

The most reliable metric for determination of impact is the number of citations a paper receives. It is not a perfect metric; many important papers languished in obscure journals for many years before their importance is discovered. The paper describing the synthesis of aspirin lay dormant in a chemical journal for almost a century before being discovered by pharmacologists working for the German Bayer company. But as a rule, measuring a paper’s impact by the number of citations it receives in subsequent publications is a pretty good indicator of its impact on the field.

So what does the mirror on the wall tell us about who is the most impactful of them all? An analysis produced by Thomson Reuters came up with a surprising result: Scientific papers from the U.K have the greatest impact in the world when the six most prolific nations are ranked by average number of citations. Britain only produced 8% of the world’s research articles and reviews but averaged 17% of the world’s research papers with more than 500 citations and 20% of those with more than 1,000 citations. The U.K performance surpassed the U.S. from second to first rank in 2007. Germany went from fourth place in 1991 to second place in 2010, knocking the United States down to third place last year.

Impact of scientific papers (data obtained from Thomson Reuters research)

The Thomson Reuters report says that the “rising trajectory” of U.K. research stands in contrast to the U.S record, which “has at best plateaued in performance and, according to some estimates, is now in decline.”


Will they ever learn?

With a group of troglodytes now holding sway in the halls of Congress, I am quite pessimistic. Hostility to Science is now in vogue, and Presidential candidates compete in brandishing their credentials as ignorami.

American exceptionalism? Bah humbug!

Dov Michaeli, MD, PhD
Dov Michaeli, MD, PhD loves to write about the brain and human behavior as well as translate complicated basic science concepts into entertainment for the rest of us. He was a professor at the University of California San Francisco before leaving to enter the world of biotech. He served as the Chief Medical Officer of biotech companies, including Aphton Corporation. He also founded and served as the CEO of Madah Medica, an early stage biotech company developing products to improve post-surgical pain control. He is now retired and enjoys working out, following the stock market, travelling the world, and, of course, writing for TDWI.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.